Reviewer's report

Title: Hepatic profile analyses of tipranavir in Phase II and III clinical trials

Version: 2 Date: 18 September 2009

Reviewer: Nicola Abrescia

Reviewer's report:

The authors have modified the paper according to all suggestions except for number 4 of minor essential revision of my review letter. Indeed, in the response to my review, the authors provide a good explanation. However they do not it within the paper. They should better explain, in the paper, why the majority of patients experiencing a DAIDS 4 toxicity did not discontinued HAART, in contrast to good clinical practice and international guidelines

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.